Tenonitrozole

Tenonitrozole

SCHEMBL150446

O=C(Nc1ncc([N+](=O)[O-])s1)c1cccs1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 1.00
RAB9A P51151 11/20 1.00
MEN1 O00255 8/20 1.00
KMT2A Q03164 8/20 1.00
PKM P14618 5/20 1.00
STAT3 P40763 8/20 0.62
POLB P06746 1/20 0.60
MAPT P10636 5/20 0.59
NPSR1 Q6W5P4 2/20 0.59
THRB P10828 1/20 0.59
MAPK9 P45984 1/20 0.59
ALDH1A1 P00352 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
LMNA P02545 3/20 0.57
HTT P42858 2/20 0.57
ABL1 P00519 3/20 0.56
TP53 P04637 2/20 0.56
MAPK1 P28482 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375564 0.82 NPC1 (0.69) NPC1RAB9AMEN1KMT2APKM
SCHEMBL1804666 0.80 NPC1 (0.76) NPC1RAB9AMEN1KMT2APKM
SCHEMBL881752 0.79 STAT3 (0.67) NPC1RAB9AMEN1KMT2APKM
SCHEMBL881750 0.78 NPC1 (0.64) NPC1RAB9AMEN1KMT2APKM
SCHEMBL10253097 0.78 RAB9A (1.00) NPC1RAB9AMEN1KMT2APKM
SCHEMBL27135379 0.78 STAT3 (0.70) NPC1RAB9AMEN1KMT2APKM
SCHEMBL17732647 0.78 NPC1 (0.63) NPC1RAB9AMEN1KMT2APKM
SCHEMBL13694244 0.77 NSUN3 (0.78) NPC1RAB9AMEN1KMT2APKM
SCHEMBL11154311 0.77 STAT3 (0.79) NPC1RAB9AMEN1KMT2APKM
SCHEMBL876378 0.77 STAT3 (0.64) NPC1RAB9AMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076059-A1 ROCAGLATE DERIVATIVES AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-04-10 WO claimed
US-20250099557-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) 2025-03-27 US claimed
EP-4374848-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION Shanghai Bao Pharmaceuticals Co., Ltd. (CN) 2024-05-29 EP claimed
WO-2019075011-A1 EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2019-04-18 WO claimed
WO-2018017426-A1 COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2018-01-25 WO claimed
US-20180015153-A1 COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2018-01-18 US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
CN-105492004-A Method of treating topical microbial infections LUODA PHARMA PTY LTD 2016-04-13 CN claimed
CN-105492005-A Methods of treating microbial infections including mastitis LUODA PHARMA PTY LTD 2016-04-13 CN claimed
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS Luoda Pharma Limited (IE) 2016-01-07 US claimed
US-20030007826-A1 Adhesive treatment for tinea pedis CLOSURE MEDICAL CORPORATION 2003-01-09 US claimed
US-20030007947-A1 Adhesive treatment for oral fungal infection CLOSURE MEDICAL CORPORATION (US) 2003-01-09 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811078-A IN A SOLVENT MIXTURE WITH ETHYL OR ISOPROPYL ALCOHOL AND WATER ADOLOR CORPORATION (US) 1998-09-22 US claimed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 EP claimed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 WO claimed
EP-0306389-B1 USE OF MICROCAPSULES IN THE MANUFACTURE OF AN ELASTOMERIC PROPHYLACTIC DEVICE, SUCH AS A CONDOM OR THE LIKE, AND ITS MANUFACTURING PROCESS HUTCHINSON (FR) 1992-07-08 EP claimed
CN-1031648-A Prevent mean that elastomeric material is made and manufacture method thereof HUTCHINSON (FR) 1989-03-15 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160000748-A1 METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS TSLP, CCL11, IL17A NPC1 268/4885RAB9A 2414/4885MEN1 3888/4885
US-20180015153-A1 COMPOUNDS AND METHODS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION CDK2, CDKN1A, PSENEN NPC1 1989/4885RAB9A 1540/4885MEN1 1144/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS NPC1 282/4885RAB9A 3198/4885MEN1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.